These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 35849246)

  • 1. Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.
    Wakiya R; Ueeda K; Shimada H; Nakashima S; Kameda T; Miyatake N; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
    Clin Rheumatol; 2022 Nov; 41(11):3345-3353. PubMed ID: 35849246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
    Monzavi SM; Alirezaei A; Shariati-Sarabi Z; Tavakol Afshari J; Mahmoudi M; Dormanesh B; Jahandoost F; Khoshdel AR; Etemad Rezaie A
    Inflammopharmacology; 2018 Oct; 26(5):1175-1182. PubMed ID: 29987550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.
    Lang MG; Vinagre CG; Bonfa E; Freitas FR; Pasoto SG; Brito TS; Seguro LP; Maranhão RC; Borba EF
    Lupus; 2022 May; 31(6):659-665. PubMed ID: 35332823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus.
    Yoshida M; Minowa K; Amano H; Asai Y; Yamaji K; Tamura N
    Lupus; 2021 Aug; 30(9):1378-1384. PubMed ID: 33966540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
    Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
    Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
    Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum adipokine levels and associations with patient-reported fatigue in systemic lupus erythematosus.
    Mahieu MA; Ahn GE; Chmiel JS; Dunlop DD; Helenowski IB; Semanik P; Song J; Yount S; Chang RW; Ramsey-Goldman R
    Rheumatol Int; 2018 Jun; 38(6):1053-1061. PubMed ID: 29302804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adipokine interactions promote the pathogenesis of systemic lupus erythematosus.
    Chougule D; Nadkar M; Venkataraman K; Rajadhyaksha A; Hase N; Jamale T; Kini S; Khadilkar P; Anand V; Madkaikar M; Pradhan V
    Cytokine; 2018 Nov; 111():20-27. PubMed ID: 30098476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus.
    Wakiya R; Kameda T; Ueeda K; Nakashima S; Shimada H; Mansour MF; Kato M; Miyagi T; Miyatake N; Kadowaki N; Dobashi H
    Lupus; 2019 Jun; 28(7):826-833. PubMed ID: 31068068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
    Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
    Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus.
    Wakiya R; Ueeda K; Nakashima S; Shimada H; Kameda T; Mansour MMF; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
    Sci Rep; 2022 Jun; 12(1):10175. PubMed ID: 35715525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus.
    Yang J; Yang X; Yang J; Li M
    J Rheumatol; 2018 Jun; 45(6):818-826. PubMed ID: 29545450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
    Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.
    Salgado Guerrero M; Londono Jimenez A; Dobrowolski C; Mowrey WB; Goilav B; Wang S; Broder A
    BMC Nephrol; 2020 Oct; 21(1):450. PubMed ID: 33115441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
    Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
    Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
    Morita S; Takahashi T; Yoshida Y; Yokota N
    Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.